Imvacs
Imvacs

Cambridge Healthtech Institute’s Eleventh Annual
Vaccine Adjuvants
Part of the Eleventh Annual ImVacS: Immunization and Vaccine Summit
December 8-9, 2016 | Revere Hotel | Boston, MA


Many recently developed vaccines are comprised of recombinant molecules or subunits of pathogenic organisms, requiring formulation with adjuvants to increase and direct the immune response. The benefit of adjuvants is clear: they may reduce the amount of antigen and number of vaccinations needed, accelerate the immune response, increase cross-protection, and improve efficacy in populations that are poor responders. As we continue to confront emerging and re-emerging disease threats and progress toward developing new vaccines to improve global health, there is also an urgent need for the development of effective adjuvants. CHI’s Eleventh Annual Vaccine Adjuvants meeting will cover the latest advances in a range of adjuvants, including understanding mode of action, and present case studies of successful formulations against challenging diseases.

Preliminary Agenda


INNOVATIONS IN LIPOSOMAL ADJUVANTS

Liposomes as Human Vaccine Adjuvants

Carl Alving, M.D., Chief, Laboratory of Adjuvant & Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research

Cationic Liposomes (CAF01) - Mode of Action and Potential for Vaccination Strategies Targeting the Mucosa

Peter L. Andersen, DVM, DMSc, Professor, Vice President, Vaccine R&D Division of Vaccine, Statens Serum Institute


NEXT-GENERATION ADJUVANTS

Designing and Building the Next Generation of Vaccine Adjuvants

Derek O’Hagan, Ph.D., Global Head, Vaccine Chemistry & Formulation Research, GlaxoSmithKline Vaccines

Influenza Vaccine Improvements: Adjuvants, Cell and Beyond

Ethan Settembre, Ph.D., Head, Research, Seqirus

 


TLR AGONIST ADJUVANTS

Activity of TLR Agonists

Dennis Klinman, M.D., Ph.D., Senior Investigator, Cancer and Inflammation Program, NCI, NIH

Induction of Robust and Diverse T Cell Responses by the TLR2-Ligand Based Adjuvant, Meningococcal PorB

Lee M. Wetzler, M.D., Co-Director for Research, Section of Infectious Diseases, Professor of Medicine and Microbiology, Boston University School of Medicine

Evaluation of the Antibody Threshold of Protection Conferred by a Next-Generation Anthrax Vaccine Candidate Adjuvanted with the Immunostimulatory CPG 7909 TLR9 Agonist

Mario Skiadopoulos, Ph.D., Senior Director, Product Development, Emergent BioSolutions

 


COMBINATION ADJUVANTS

Combination Adjuvants for Cancer Immunotherapy

Lakshmi Krishnan, Ph.D., Program Leader, Vaccines and Human Health Therapeutics, National Research Council, Canada


MODE OF ACTION OF VACCINE ADJUVANTS

Uncovering Innate Immune Pathways that Contribute to the Efficacy of Lipid Nanoparticle-Based Vaccine Formulations

Gokul Swaminathan, Ph.D., Senior Scientist, Infectious Diseases & Vaccines, Merck Research Laboratories, Merck & Co., Inc.

Formulation Development and Biological Activity of Isoprenoid-Based Nanoemulsion Adjuvants

Karina Smolyar, Formulation Development, Infectious Disease Research Institute




For more details on the conference, please contact:
Virginia Maxwell
Senior Associate Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5436
E: vmaxwell@healthtech.com

For exhibit & sponsorship opportunities, please contact:
Uma Patel
Business Development Manager
781-972-1349
upatel@healthtech.com